Abstract
Seventy-one cases of possible diplopia associated with cholesterol- lowering, HMG-CoA reductase inhibitors lovastatin, simvastatin, pravastatin, or fluvastatin are reviewed. Cases were received from spontaneous reporting systems, and while these data are incomplete, two cases recurred on rechallenge and 31 had positive dechallenge tests. This suggests that these agents may cause diplopia in some patients. Diplopia may be a potential marker of these agents' drug-induced, generalized muscle dysfunction.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 287-289 |
| Number of pages | 3 |
| Journal | Journal of Toxicology - Cutaneous and Ocular Toxicology |
| Volume | 18 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jan 1 1999 |
ASJC Scopus subject areas
- Ophthalmology
- Toxicology
- Health, Toxicology and Mutagenesis
Fingerprint Dive into the research topics of 'Diplopia and HMG-CoA reductase inhibitors'. Together they form a unique fingerprint.
Cite this
Fraunfelder, F. W., Fraunfelder, F. T., & Edwards, R. (1999). Diplopia and HMG-CoA reductase inhibitors. Journal of Toxicology - Cutaneous and Ocular Toxicology, 18(4), 287-289. https://doi.org/10.3109/15569529909065546